Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group

Raymond Y. Huang, Wenya Linda Bi, Michael Weller, Thomas Kaley, Jaishri Blakeley, Ian Dunn, Evanthia Galanis, Matthias Preusser, Michael McDermott, Leland Rogers, Jeffrey Raizer, David Schiff, Riccardo Soffietti, Jörg Christian Tonn, Michael Vogelbaum, Damien Weber, David A. Reardon, Patrick Y. Wen

Research output: Contribution to journalArticle

Abstract

No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

Original languageEnglish (US)
Pages (from-to)26-36
Number of pages11
JournalNeuro-Oncology
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Huang, R. Y., Bi, W. L., Weller, M., Kaley, T., Blakeley, J., Dunn, I., Galanis, E., Preusser, M., McDermott, M., Rogers, L., Raizer, J., Schiff, D., Soffietti, R., Tonn, J. C., Vogelbaum, M., Weber, D., Reardon, D. A., & Wen, P. Y. (2019). Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 21(1), 26-36. https://doi.org/10.1093/neuonc/noy137